GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioRestorative Therapies Inc (NAS:BRTX) » Definitions » Asset Turnover

BRTX (BioRestorative Therapies) Asset Turnover : 0.02 (As of Sep. 2024)


View and export this data going back to 2021. Start your Free Trial

What is BioRestorative Therapies Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. BioRestorative Therapies's Revenue for the three months ended in Sep. 2024 was $0.23 Mil. BioRestorative Therapies's Total Assets for the quarter that ended in Sep. 2024 was $15.35 Mil. Therefore, BioRestorative Therapies's Asset Turnover for the quarter that ended in Sep. 2024 was 0.02.

Asset Turnover is linked to ROE % through Du Pont Formula. BioRestorative Therapies's annualized ROE % for the quarter that ended in Sep. 2024 was -41.98%. It is also linked to ROA % through Du Pont Formula. BioRestorative Therapies's annualized ROA % for the quarter that ended in Sep. 2024 was -28.44%.


BioRestorative Therapies Asset Turnover Historical Data

The historical data trend for BioRestorative Therapies's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioRestorative Therapies Asset Turnover Chart

BioRestorative Therapies Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Asset Turnover
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.10 0.03 - 0.01 0.01

BioRestorative Therapies Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - 0.01 0.02

Competitive Comparison of BioRestorative Therapies's Asset Turnover

For the Biotechnology subindustry, BioRestorative Therapies's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioRestorative Therapies's Asset Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioRestorative Therapies's Asset Turnover distribution charts can be found below:

* The bar in red indicates where BioRestorative Therapies's Asset Turnover falls into.



BioRestorative Therapies Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

BioRestorative Therapies's Asset Turnover for the fiscal year that ended in Dec. 2023 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=0.146/( (16.435+12.612)/ 2 )
=0.146/14.5235
=0.01

BioRestorative Therapies's Asset Turnover for the quarter that ended in Sep. 2024 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Sep. 2024 )/( (Total Assets (Q: Jun. 2024 )+Total Assets (Q: Sep. 2024 ))/ count )
=0.234/( (16.119+14.573)/ 2 )
=0.234/15.346
=0.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


BioRestorative Therapies  (NAS:BRTX) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

BioRestorative Therapies's annulized ROE % for the quarter that ended in Sep. 2024 is

ROE %**(Q: Sep. 2024 )
=Net Income/Total Stockholders Equity
=-4.364/10.3955
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-4.364 / 0.936)*(0.936 / 15.346)*(15.346/ 10.3955)
=Net Margin %*Asset Turnover*Equity Multiplier
=-466.24 %*0.061*1.4762
=ROA %*Equity Multiplier
=-28.44 %*1.4762
=-41.98 %

Note: The Net Income data used here is four times the quarterly (Sep. 2024) net income data. The Revenue data used here is four times the quarterly (Sep. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

BioRestorative Therapies's annulized ROA % for the quarter that ended in Sep. 2024 is

ROA %(Q: Sep. 2024 )
=Net Income/Total Assets
=-4.364/15.346
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-4.364 / 0.936)*(0.936 / 15.346)
=Net Margin %*Asset Turnover
=-466.24 %*0.061
=-28.44 %

Note: The Net Income data used here is four times the quarterly (Sep. 2024) net income data. The Revenue data used here is four times the quarterly (Sep. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


BioRestorative Therapies Asset Turnover Related Terms

Thank you for viewing the detailed overview of BioRestorative Therapies's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


BioRestorative Therapies Business Description

Traded in Other Exchanges
Address
40 Marcus Drive, Suite One, Melville, NY, USA, 11747
BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, primarily involving adult (non-embryonic) stem cells. The company's two core development programs include the Disc/Spine Program, which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow; and the Metabolic Program, which includes the development of cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue.
Executives
Dale Broadrick 10 percent owner 3003 BRICK CHURCH PIKE, NASHVILLE TN 37207
Francisco Silva director, 10 percent owner, officer: VP of Research and Development STEM CELL ASSURANCE, INC., 555 HERITAGE DRIVE, JUPITER FL 33458
Lance Alstodt director, 10 percent owner, officer: President, CEO, COB BIORESTORATIVE THERAPIES, INC., 40 MARCUS DRIVE, SUITE 1, MELVILLE NY 11747
Robert Eugene Kristal officer: Chief Financial Officer 4719 COLE AVENUE, DALLAS TX 75205
Patrick F. Williams director C/O ZELTIQ AESTHETICS INC., 4698 WILLOW ROAD, SUITE 100, PLEASANTON CA 94588
David A Rosa director 10901 RED CIRCLE DRIVE, SUITE 150, MINNETONKA MN 55343
Nickolay V. Kukekov director 4524 WESTWAY AVE, DALLAS TX 75205
Mark Weinreb director, 10 percent owner, officer: CEO and Chairman of the Board STEM CELL ASSURANCE, INC., 555 HERITAGE DRIVE, JUPITER FL 33458
Paul Jude Tonna director 69 CHICHESTER ROAD, HUNTINGTON NY 11743
A. Jeffrey Radov director 8 WALWORTH AVENUE, SCARSDALE NY 10583
Robert Paccasassi officer: VP, Quality and Compliance C/O BIORESTORATIVE THERAPIES, INC., 40 MARCUS DRIVE, SUITE 1, MELVILLE NY 11747
Robert B Catell director 62 OSBORNE ROAD, GARDEN CITY NY 11530
Adam D. Bergstein officer: SVP, Planning and Business Dev 167 HAZEL AVENUE, GLENCOE IL 60022
John M Desmarais director 230 PARK AVENUE, NEW YORK NY 10169
Westbury Trust 10 percent owner VICTORIA HALL, 11 VICTORIA STREET, P.O. BOX HM 1065, HAMILTON D0 00000